6:05 PM
 | 
Nov 06, 2012
 |  BC Extra  |  Top Story

FDA approves tofacitinib for RA

FDA approved an NDA from Pfizer Inc. (NYSE:PFE) for Xeljanz tofacitinib to treat moderate to severe rheumatoid arthritis in adults with an inadequate response or intolerance to methotrexate. Xeljanz may be used as monotherapy or in combination with methotrexate...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >